DNX-2440 for Resectable Colorectal Liver Metastasis

Key Inclusion Criteria: * Male or female aged ≥ 18 years at time of consent * Diagnosis of liver metastases from colorectal, breast, gastric, periampullary, melanoma, renal cell cancer, sarcoma, squamous cell carcinoma or gastrointestinal stromal tumor * Multiple (≥ 2) liver tumors * Candidate for curative-intent surgery * Stated willingness to comply with all study procedures and availability for the duration of the study. * Candidates eligible for targeted therapy, as per standard of care guidelines (and based on mutational status as indicated), must have completed therapy * Preoperative chemotherapy is allowed Key Exclusion Criteria: * Recurrence of liver metastasis * Diagnosis of neuroendocrine tumor liver metastasis * Liver metastasis treated with \> 12 cycles of systemic chemotherapy * Condition that requires ongoing systemic immunosuppressive therapy * Evidence of inadequate organ function based on lab parameters * Liver transaminases (aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\]) or total bilirubin \> 5x the upper limits of normal * Males or females who refuse to use a double-barrier form of birth control during the study and for up to 6 months after injection with DNX-2440